Quarterly ResultAug 6, 2026, 08:16 AM
Delcath Systems Q2 Revenue $29.1M; Raises 2026 Guidance to $104M-$108M
AI Summary
Delcath Systems announced its second quarter 2026 financial results, reporting total revenue of $29.1 million, an increase from $24.2 million in the prior year. The company also raised its full-year 2026 revenue guidance to a range of $104 million to $108 million. While net income remained flat at $2.7 million, non-GAAP adjusted EBITDA decreased to $7.6 million from $9.8 million year-over-year. Business highlights included 30% growth in HEPZATO volume and the dosing of the first patient in a global Phase 2 trial for HEPZATO in metastatic breast cancer.
Key Highlights
- Increased 2026 full-year revenue guidance to a range of $104 million to $108 million.
- Reported total revenue of $29.1 million for Q2 2026, up from $24.2 million in Q2 2025.
- HEPZATO KIT revenue reached $27.1 million, compared to $22.5 million in Q2 2025.
- Net income was $2.7 million for both Q2 2026 and Q2 2025.
- Non-GAAP adjusted EBITDA was $7.6 million, down from $9.8 million in Q2 2025.
- Cash provided by operations was $5.7 million in the second quarter.
- Cash and investments totaled $95.9 million as of June 30, 2026.
- Achieved approximately 30% growth in HEPZATO volume in Q2 2026 year-over-year.
Price Impact
More from DCTH